Tivozanib ATC:L01EK03

TENDER DESCRIPTION

Kaufmännische Krankenkasse - KKH (hereinafter referred to as KKH) pursues the objective of concluding discount agreements in accordance with Section 130a(8) of SGB V with all suitable pharmaceutical companies for the active ingredient stated under BT-21-Lot (ATC) and, if applicable, restricting them to certain dosage forms as part of a so-called "Open-House procedure". Subject to uniform contractual terms and a uniform access procedure, the conclusion or accession to a discount agreement in accordance with Section 130a(8) of SGB V for the above-mentioned active ingredient is offered to all suitable and interested pharmaceutical companies or associations of pharmaceutical companies. Interested pharmaceutical companies may request the participation documents as well as the contract from the contact address stated. A condition for concluding a contract is that the interested pharmaceutical company submits the requested participation documents fully completed and signed. A contract is concluded with each pharmaceutical company that meets the participation requirements. Exclusivity is not provided. Accession and/or contract conclusion may take place at any time and under the same…

TENDER BRIEF

TENDER DOCUMENTS